Covid-19 / hospital-acquired infections / multi drug resistance, page-3

pierre,

waiting and waiting is so boring. The deal must come soon, but it is perhaps more complex than we can understand with the "action fund", big pharma companies, and many small companies. The action fund needs to find its role, Alterity has no bacterial experience, Stamler lives in California, Kempler perhaps as a consultant in Australia, the fund in Europa, 3 big pharma Pfizer in NY, Teva in Israel, Novartis in Basel, etc. In any case, my estimate is that there are still some 300 daily deaths in the USA because of Covid and antibiotic-resistant infections.

2019 AR Threats Report

CDC’s Antibiotic Resistance Threats in the United States, 2019 (2019 AR Threats Report) includes the latest national death and infection estimates that underscore the continued threat of antibiotic resistance in the U.S.

According to the report, more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. In addition, 223,900 cases of Clostridioides difficile occurred in 2017 and at least 12,800 people died.

I try to activate the April 2021 report:
CDC Partners Estimate Healthcare Cost of Antibiotic-resistant Infections | Antibiotic/Antimicrobial Resistance | CDC